Ivermectin to reduce malaria transmission III. Considerations regarding regulatory and policy pathways

Malaria Journal

Volumn 16, Issue 1, 2017, Pages

  Chaccour, Carlos ^a,b,c   Rabinovich, N Regina ^a,d  

^a UNIVERSITY OF BARCELONA   (Spain)

^b Manhiça Health Research Center   (Mozambique)

^c UNIVERSITY OF NAVARRA   (Spain)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Anopheles; Endectocide; Ivermectin; Malaria; Policy; Regulatory pathway

Indexed keywords

IVERMECTIN; PRIMAQUINE; INSECTICIDE;

COST EFFECTIVENESS ANALYSIS; DISEASE ELIMINATION; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; EUROPEAN MEDICINES AGENCY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HEALTH PROGRAM; HUMAN; LICENSING; LOW DRUG DOSE; MALARIA; MASS DRUG ADMINISTRATION; MICROFILARIASIS; ONCHOCERCIASIS; PEDICULOSIS CAPITIS; REVIEW; ROSACEA; SCABIES; SINGLE DRUG DOSE; STRONGYLOIDIASIS; WORLD HEALTH ORGANIZATION; ANIMAL; ANOPHELES; GOVERNMENT REGULATION; LEGISLATION AND JURISPRUDENCE; MOSQUITO CONTROL;

ANIMALS; ANOPHELES; GOVERNMENT REGULATION; HEALTH POLICY; INSECTICIDES; IVERMECTIN; MALARIA; MOSQUITO CONTROL;

EID: 85018548664     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/s12936-017-1803-2     Document Type: Review

References (72)

1. Merck-&-Co. Stromectrol. FDA approved Package insert 2009. http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/050742s026lbl.pdf. Accessed Oct 2016.
2. Sanofi-SA. Sklice. FDA approved package insert 2012. http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/202736s000lbl.pdf. Accessed Feb 2017.
3. Galderma-SA. Soolantra. FDA approved package insert 2014. http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/206255lbl.pdf. Accessed Feb 2017.
4. Ministere-des-affaires-sociales-de-la-sante-et-des-droits-des-femmes. STROMECTOL 3 mg, comprimé-Résumé des caractéristiques du produit. http://base-donnees-publiquemedicamentsgouvfr/affichageDocphp?specid=61350360&typedoc=R. Accessed Aug 2016.
5. Merck-&-Co. Stromectrol. TGA-Australia approved Package insert 2014. https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2011-PI-02659-3&d=2016071016114622483. Accessed Feb 2017.
6. da Cruz FP, Martin C, Buchholz K, Lafuente-Monasterio MJ, Rodrigues T, Sonnichsen B, et al. Drug screen targeted at Plasmodium liver stages identifies a potent multistage antimalarial drug. J Infect Dis. 2012;205:1278-86.
7. Mendes AM, Albuquerque IS, Machado M, Pissarra J, Meireles P, Prudencio M. Inhibition of Plasmodium liver infection by ivermectin. Antimicrob Agents Chemother. 2017;61:02005-16.
8. Foy BD. Results from RIMDAMAL, a pilot randomized cluster-design trial in Burkina Faso, designed to assess the safety and efficacy of repeat ivermectin mass drug administrations to control malaria and NTDs. Oral presentation during the 65th Annual Meeting of the ASTMH Atlanta 2016.
9. WHO. Policy brief on single-dose primaquine as a gametocytocide in Plasmodium falciparum malaria. Geneva: World Health Organization. http://www.who.int/malaria/publications/atoz/who-htm-gmp-2015.1.pdf?ua=1. Accessed Mar 2017.
10. Nunes JK, Woods C, Carter T, Raphael T, Morin MJ, Diallo D, et al. Development of a transmission-blocking malaria vaccine: progress, challenges, and the path forward. Vaccine. 2014;32:5531-9.
11. FDA. Guidance for industry. Applications covered by section 505(b)(2). http://www.fdagov/downloads/Drugs/Guidances/ucm079345pdf. Accessed Aug 2015.
12. FDA. Guidance for Industry Malaria: developing drug and nonvaccine biological products for treatment and prophylaxis. http://www.fdagov/downloads/Drugs/Guidances/ucm071951pdf. Accessed Aug 2015.
13. FDA. Guidance for Industry. Providing clinical evidence of effectiveness for human drug and biological products. http://www.fdagov/downloads/Drugs//Guidances/ucm078749pdf. Accessed Aug 2015.
14. FDA. Guidance for industry and investigators. Safety reporting requirements for INDs and BA/BE studies. http://www.fdagov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM227351pdf. Accessed Aug 2015.
15. Chaccour C, Rabinovich NR. Ivermectin to reduce malaria transmission II. Considerations regarding clinical development pathway. Malar J (submitted).
16. Alonso PL, Lindsay SW, Armstrong JR, Conteh M, Hill AG, David PH, et al. The effect of insecticide-treated bed nets on mortality of Gambian children. Lancet. 1991;337:1499-502.
17. FDA. Guidance for Industry. Expedited programs for serious conditions - drugs and biologics. http://www.fdagov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm358301pdf. Accessed Aug 2015.
18. Fleming TR. Surrogate endpoints and FDA's accelerated approval process. Health Aff (Millwood). 2005;24:67-78.
19. Chaccour C, Hammann F, Rabinovich NR. Ivermectin to reduce malaria transmission I. Pharmacokinetic considerations regarding efficacy and safety. Malar J (submitted).
20. WHO. WHO preferred product characteristics (PPC) for malaria vaccines. Geneva: World Health Organization; 2014.
21. Slater HKK, Foy B, Alout H, Churcher T, Bousema T, Ghani A. Ivermectin for malaria control: model validation to existing data and designing trials to detect an impact using clinical and entomological metrics. In 64th Annual meeting of the American Society of Tropical Medicine and Hygiene; 2015 Oct 25-29; Philadelphia.
22. Slater HC, Walker PG, Bousema T, Okell LC, Ghani AC. The potential impact of adding ivermectin to a mass treatment intervention to reduce malaria transmission: a modelling study. J Infect Dis. 2014;210:1972-80.
23. Bellinger AM, Jafari M, Grant TM, Zhang S, Slater HC, Wenger EA, et al. Oral, ultra-long-lasting drug delivery: application toward malaria elimination goals. Sci Transl Med. 2016;8:365ra157.
24. White NJ. Primaquine to prevent transmission of falciparum malaria. Lancet Infect Dis. 2013;13:175-81.
25. Burrows JN, van Huijsduijnen RH, Mohrle JJ, Oeuvray C, Wells TN. Designing the next generation of medicines for malaria control and eradication. Malar J. 2013;12:187.
26. WHO. Prequalification programme. http://appswhoint/prequal/defaulthtml. Accessed Aug 2015.
27. WHO. Prequalification Scheme. List of APIs and FPP invited for prequalification. http://apps.who.int/prequal/info-applicants/eoi/FPPs-APIs-invited.xlsx. Accessed July 2016.
28. Mectizan Donation Program. Annual highlights 2015. http://www.mectizan.org/sites/www.mectizan.org/files/attachments/resources/MDP-AnnHigh2015-Design%20041516FINAL2%20%281%29.pdf. Accessed Aug 2016.
29. Agence Nationale de sécurité du Médicament et des produits de santé. Stromectol 3 mg. http://base-donnees-publique.medicaments.gouv.fr/affichageDoc.php?specid=61350360&typedoc=R#Rcp-6-1-ListeExcipients-4. Accessed June 2015.
30. Centers for Medicare & Medicaid Services. https://data.medicaid.gov/Drug-Prices/NADAC-as-of-2017-01-04/xbye-fzdt. Accessed Jan 2017.
31. Brooks A, Nunes JK, Garnett A, Biellik R, Leboulleux D, Birkett AJ, et al. Aligning new interventions with developing country health systems: target product profiles, presentation, and clinical trial design. Glob Public Health. 2012;7:931-45.
32. Milstien J, Cardenas V, Cheyne J, Brooks A. WHO policy development processes for a new vaccine: case study of malaria vaccines. Malar J. 2010;9:182.
33. Centers for Disease Control and Prevention (CDC). Prescription medication for the treatment of scabies. http://www.cdc.gov/parasites/scabies/health-professionals/meds.html. Accessed June 2016.
34. Butters MP, Kobylinski KC, Deus KM, da Silva IM, Gray M, Sylla M, et al. Comparative evaluation of systemic drugs for their effects against Anopheles gambiae. Acta Trop. 2012;121:34-43.
35. Poche RM, Burruss D, Polyakova L, Poche DM, Garlapati RB. Treatment of livestock with systemic insecticides for control of Anopheles arabiensis in western Kenya. Malar J. 2015;14:351.
36. Pacque M, Munoz B, Greene BM, Taylor HR. Community-based treatment of onchocerciasis with ivermectin: safety, efficacy, and acceptability of yearly treatment. J Infect Dis. 1991;163:381-5.
37. Kelly-Hope LA, Cano J, Stanton MC, Bockarie MJ, Molyneux DH. Innovative tools for assessing risks for severe adverse events in areas of overlapping Loa loa and other filarial distributions: the application of micro-stratification mapping. Parasit Vectors. 2014;7:307.
38. D'Ambrosio MV, Bakalar M, Bennuru S, Reber C, Skandarajah A, Nilsson L, et al. Point-of-care quantification of blood-borne filarial parasites with a mobile phone microscope. Sci Transl Med. 2015;7:286re4.
39. WHO. Preventive chemotherapy in human helminthiasis. Coordinated use of anthelminthic drugs in control interventions. A manual for health professionals and programme managers. http://apps.who.int/iris/bitstream/10665/43545/1/9241547103-eng.pdf. Accessed Aug 2016.
40. Zoure HG, Noma M, Tekle AH, Amazigo UV, Diggle PJ, Giorgi E, et al. The geographic distribution of onchocerciasis in the 20 participating countries of the African Programme for Onchocerciasis Control: (2) pre-control endemicity levels and estimated number infected. Parasit Vectors. 2014;7:326.
41. Bhatt S, Weiss DJ, Cameron E, Bisanzio D, Mappin B, Dalrymple U, et al. The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015. Nature. 2015;526:207-11.
42. Frempong KK, Walker M, Cheke RA, Tetevi EJ, Gyan ET, Owusu EO, et al. Does increasing treatment frequency address suboptimal responses to ivermectin for the control and elimination of river blindness? Clin Infect Dis. 2016;62:1338-47.
43. Katabarwa M, Richards F. Twice-yearly ivermectin for onchocerciasis: the time is now. Lancet Infect Dis. 2014;14:373-4.
44. Irvine MA, Stolk WA, Smith ME, Subramanian S, Singh BK, Weil GJ, et al. Effectiveness of a triple-drug regimen for global elimination of lymphatic filariasis: a modelling study. Lancet Infect Dis. 2016;17:451-8.
45. Omura S, Crump A. Ivermectin: panacea for resource-poor communities? Trends Parasitol. 2014;30:445-55.
46. Kobylinski KC, Alout H, Foy BD, Clements A, Adisakwattana P, Swierczewski BE, et al. Rationale for the coadministration of albendazole and ivermectin to humans for malaria parasite transmission control. Am J Trop Med Hyg. 2014;91:655-62.
47. Thomsen EK, Sanuku N, Baea M, Satofan S, Maki E, Lombore B, et al. Efficacy, safety, and pharmacokinetics of coadministered diethylcarbamazine, albendazole, and ivermectin for treatment of Bancroftian filariasis. Clin Infect Dis. 2016;62:334-41.
48. Osei-Atweneboana MY, Eng JK, Boakye DA, Gyapong JO, Prichard RK. Prevalence and intensity of Onchocerca volvulus infection and efficacy of ivermectin in endemic communities in Ghana: a two-phase epidemiological study. Lancet. 2007;369:2021-9.
49. Burnham G. Efficacy of ivermectin against Onchocerca volvulus in Ghana. Lancet. 2007;370:1125.
50. Cupp E, Richards F, Lammie P, Eberhard M. Efficacy of ivermectin against Onchocerca volvulus in Ghana. Lancet. 2007;370:1123 (author reply 24-5).
51. Mackenzie CD. Efficacy of ivermectin against Onchocerca volvulus in Ghana. Lancet. 2007;370:1123 (author reply 24-5).
52. Remme JH, Amazigo U, Engels D, Barryson A, Yameogo L. Efficacy of ivermectin against Onchocerca volvulus in Ghana. Lancet. 2007;370:1123-4 (author reply 24-5).
53. Richards FO, Emukah E, Graves PM, Nkwocha O, Nwankwo L, Rakers L, et al. Community-wide distribution of long-lasting insecticidal nets can halt transmission of lymphatic filariasis in southeastern Nigeria. Am J Trop Med Hyg. 2013;89:578-87.
54. Turner HC, Walker M, Attah SK, Opoku NO, Awadzi K, Kuesel AC, et al. The potential impact of moxidectin on onchocerciasis elimination in Africa: an economic evaluation based on the Phase II clinical trial data. Parasit Vectors. 2015;8:167.
55. Shoop WL, Mrozik H, Fisher MH. Structure and activity of avermectins and milbemycins in animal health. Vet Parasitol. 1995;59:139-56.
56. Conder GA, Thompson DP, Johnson SS. Demonstration of co-resistance of Haemonchus contortus to ivermectin and moxidectin. Vet Rec. 1993;132:651-2.
57. Cotreau MM, Warren S, Ryan JL, Fleckenstein L, Vanapalli SR, Brown KR, et al. The antiparasitic moxidectin: safety, tolerability, and pharmacokinetics in humans. J Clin Pharmacol. 2003;43:1108-15.
58. Dial NJ, Ceesay SJ, Gosling RD, D'Alessandro U, Baltzell KA. A qualitative study to assess community barriers to malaria mass drug administration trials in The Gambia. Malar J. 2014;13:47.
59. Minzi O, Maige S, Sasi P, Ngasala B. Adherence to artemether-lumefantrine drug combination: a rural community experience six years after change of malaria treatment policy in Tanzania. Malar J. 2014;13:267.
60. Uniting to combat NTDs: The London declaration. http://unitingtocombatntds.org/sites/default/files/resource-file/london-declaration-on-ntds.pdf. Accessed Aug 2016.
61. WHO. Guidelines for cost-effectiveness analysis of vector control. http://www.whoint/malaria/publications/atoz/who-cds-93-4/en/. Accessed Aug 2015.
62. White MT, Conteh L, Cibulskis R, Ghani AC. Costs and cost-effectiveness of malaria control interventions a systematic review. Malar J. 2011;10:337.
63. Waters HR, Rehwinkel JA, Burnham G. Economic evaluation of Mectizan distribution. Trop Med Int Health. 2004;9:A16-25.
64. Speare R, Durrheim D. Mass treatment with ivermectin: an underutilized public health strategy. Bull World Health Organ. 2004;82:562.
65. Keating J, Yukich JO, Mollenkopf S, Tediosi F. Lymphatic filariasis and onchocerciasis prevention, treatment, and control costs across diverse settings: a systematic review. Acta Trop. 2014;135:86-95.
66. Yeboah-Antwi K, Gyapong JO, Asare IK, Barnish G, Evans DB, Adjei S. Impact of prepackaging antimalarial drugs on cost to patients and compliance with treatment. Bull World Health Organ. 2001;79:394-9.
67. Burg RW, Miller BM, Baker EE, Birnbaum J, Currie SA, Hartman R, et al. Avermectins, new family of potent anthelmintic agents: producing organism and fermentation. Antimicrob Agents Chemother. 1979;15:361-7.
68. Ikeda H, Omura S. Control of avermectin biosynthesis in Streptomyces avermitilis for the selective production of a useful component. J Antibiot (Tokyo). 1995;48:549-62.
69. Zhuo Y, Zhang T, Wang Q, Cruz-Morales P, Zhang B, Liu M, et al. Synthetic biology of avermectin for production improvement and structure diversification. Biotechnol J. 2014;9:316-25.
70. MedIndia. http://www.medindia.net/drug-price/ivermectin.htm. Accessed Jan 2017.
71. Kim YE, Remme JH, Steinmann P, Stolk WA, Roungou JB, Tediosi F. Control, elimination, and eradication of river blindness: scenarios, timelines, and ivermectin treatment needs in Africa. PLoS Negl Trop Dis. 2015;9:e0003664.
72. MPAC meeting, 14-16 September 2016: Update on a proposed Ivermectin target product profile. http://www.whoint/entity/malaria/mpac/mpac-sept2016-invermectin-session9pdf?ua=1. Accessed Mar 2017.